Pieris Pharmaceuticals Statistics Share Statistics Pieris Pharmaceuticals has 1.32M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.32M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 1.08% Shares Floating 808.12K Failed to Deliver (FTD) Shares 932 FTD / Avg. Volume 4.21%
Short Selling Information The latest short interest is 27.68K, so 0% of the outstanding
shares have been sold short.
Short Interest 27.68K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.07
Valuation Ratios The PE ratio is -1.74 and the forward
PE ratio is -0.55.
Pieris Pharmaceuticals's PEG ratio is
0.03.
PE Ratio -1.74 Forward PE -0.55 PS Ratio 0 Forward PS n/a PB Ratio 0.48 P/FCF Ratio -2.79 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Pieris Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.33,
with a Debt / Equity ratio of 0.
Current Ratio 7.33 Quick Ratio 7.33 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-379K Employee Count 46 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -14.41% in the
last 52 weeks. The beta is 0.66, so Pieris Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.66 52-Week Price Change -14.41% 50-Day Moving Average 16.45 200-Day Moving Average 14.06 Relative Strength Index (RSI) 28.17 Average Volume (20 Days) 22,126
Income Statement
Revenue n/a Gross Profit n/a Operating Income n/a Net Income -17.43M EBITDA n/a EBIT n/a Earnings Per Share (EPS) -7.83
Full Income Statement Balance Sheet The company has 83.6M in cash and 0 in
debt, giving a net cash position of 83.6M.
Cash & Cash Equivalents 83.6M Total Debt n/a Net Cash n/a Retained Earnings -93.73M Total Assets 79.44M Working Capital 70.46M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.84M
and capital expenditures 0, giving a free cash flow of -10.84M.
Operating Cash Flow -10.84M Capital Expenditures n/a Free Cash Flow -10.84M FCF Per Share -4.87
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PIRS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for PIRS.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 23, 2024. It was a
backward
split with a ratio of 1:80.
Last Split Date Apr 23, 2024 Split Type backward Split Ratio 1:80
Scores Altman Z-Score -1 Piotroski F-Score 3
